Literature DB >> 29755593

Effect of stem cell transplantation of premature ovarian failure in animal models and patients: A meta-analysis and case report.

Lei Chen1, Shilei Guo1,2, Cui Wei1, Honglan Li1, Haiya Wang1, Yan Xu1,2.   

Abstract

Stem cell transplantation has been considered a promising therapeutic approach for premature ovarian failure (POF). However, to date, no quantitative data analysis of stem cell therapy for POF has been performed. Therefore, the present study performed a meta-analysis to assess the efficacy of stem cell transplantation in improving ovarian function in animal models of POF. In addition, a case report of a patient with POF subjected to stem cell treatment was included to demonstrate that stem cell therapy also contributes to the recovery of ovarian function in patients. Published studies were identified by a systematic review of the PubMed, Embase, and Cochrane's library databases, and references cited in associated reviews were also considered. Data regarding follicle-stimulating hormone (FSH), estradiol (E2), ovarian weight, follicle count, the number of pregnancies and other parameters, including delivery route and cell type, were extracted. Pooled analysis, sensitivity analyses, subgroup analyses and meta-regression were performed. In the case of POF, transvaginal ultrasound (TVS), abdominal ultrasound (TAS) and color Doppler flow imaging (CDFI) were performed to observe the endometrial morphology and blood flow signals in the patient. Overall, pooled results from 16 pre-clinical studies demonstrated that stem cell-based therapy significantly improved FSH levels [standardized mean difference (SMD)=-1.330; 95% confidence interval (CI), -(2.095-0.565); P=0.001], E2 levels (SMD=2.334; 95% CI, 1.350-3.319; P<0.001), ovarian weight (SMD=1.310; 95% CI, 0.157-2.463; P=0.026), follicle count (SMD=1.871; 95% CI, 1.226-2.516; P<0.001), and the number of pregnancies (risk ratio=1.715, 95% CI, 1.213-2.424; P=0.002). The results of TVS and TAS demonstrated improved ovarian size and endometrial thickness in the patient with POF after MSC treatment. Of note, a rich blood flow signal in the endometrium was observed on CDFI. It appeared that stem cell-based therapy may be an effective method for the resumption of ovarian function in a patient and in animal models of POF; however, large-scale and high-quality future studies are required to confirm the present findings due to heterogeneity.

Entities:  

Keywords:  cell transplantation; meta-analysis; ovarian function; premature ovarian failure; stem cell

Year:  2018        PMID: 29755593      PMCID: PMC5943678          DOI: 10.3892/etm.2018.5970

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  40 in total

Review 1.  Systematic review about breast cancer incidence in relation to hormone replacement therapy use.

Authors:  C Antoine; L Ameye; M Paesmans; S Rozenberg
Journal:  Climacteric       Date:  2013-10-29       Impact factor: 3.005

2.  Treatment of premature ovarian failure trial: description of an ongoing clinical trial.

Authors:  Beth Cartwright; Jillian Robinson; Janice Rymer
Journal:  Menopause Int       Date:  2010-03

3.  Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.

Authors:  Zeev Blumenfeld; Biren Patel; Ronit Leiba; Tsila Zuckerman
Journal:  Fertil Steril       Date:  2012-08-27       Impact factor: 7.329

Review 4.  Premature ovarian failure.

Authors:  Deepti Goswami; Gerard S Conway
Journal:  Horm Res       Date:  2007-05-09

Review 5.  Molecular aspects and clinical methods for preserving ovarian reserves in women receiving cancer treatment.

Authors:  N Thomakos; S P Trachana; I Koutroumpa; A Rodolakis; N G Gavalas
Journal:  Clin Exp Obstet Gynecol       Date:  2015       Impact factor: 0.146

6.  Induction of estrogen-sensitive epithelial cells derived from human-induced pluripotent stem cells to repair ovarian function in a chemotherapy-induced mouse model of premature ovarian failure.

Authors:  Te Liu; Wenxing Qin; Yongyi Huang; Yanhui Zhao; Jiejun Wang
Journal:  DNA Cell Biol       Date:  2013-09-14       Impact factor: 3.311

7.  Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats.

Authors:  Jiabin Liu; Haiying Zhang; Yun Zhang; Nan Li; Yuku Wen; Fanglei Cao; Hao Ai; Xiaoou Xue
Journal:  Mol Cells       Date:  2014-11-10       Impact factor: 5.034

Review 8.  Effectiveness of Autologous Stem Cell Therapy for the Treatment of Lower Extremity Ulcers: A Systematic Review and Meta-Analysis.

Authors:  Xupin Jiang; Hengshu Zhang; Miao Teng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  The Comparison of Adipose Stem Cell and Placental Stem Cell in Secretion Characteristics and in Facial Antiaging.

Authors:  Yan Xu; Shilei Guo; Cui Wei; Honglan Li; Lei Chen; Chang Yin; Chuansen Zhang
Journal:  Stem Cells Int       Date:  2016-02-08       Impact factor: 5.443

10.  Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model.

Authors:  Ahmed Badawy; Mohamed A Sobh; Mohamed Ahdy; Mohamed Sayed Abdelhafez
Journal:  Int J Womens Health       Date:  2017-06-15
View more
  12 in total

Review 1.  Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure.

Authors:  Oldouz Shareghi-Oskoue; Leili Aghebati-Maleki; Mehdi Yousefi
Journal:  Stem Cell Res Ther       Date:  2021-08-11       Impact factor: 8.079

Review 2.  Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review.

Authors:  Jeeyoon Na; Gi Jin Kim
Journal:  J Ovarian Res       Date:  2020-06-23       Impact factor: 4.234

3.  Heat shock pretreatment improves mesenchymal stem cell viability by heat shock proteins and autophagy to prevent cisplatin-induced granulosa cell apoptosis.

Authors:  Qing Wang; Xinran Li; Qingru Wang; Jiaxin Xie; Chuhai Xie; Xiafei Fu
Journal:  Stem Cell Res Ther       Date:  2019-11-26       Impact factor: 6.832

4.  Safety of Intraovarian Injection of Human Mesenchymal Stem Cells in a Premature Ovarian Insufficiency Mouse Model.

Authors:  Hang-Soo Park; Rishi Man Chugh; Amro Elsharoud; Mara Ulin; Sahar Esfandyari; Alshimaa Aboalsoud; Lale Bakir; Ayman Al-Hendy
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 5.  Exosomes as Biomarkers for Female Reproductive Diseases Diagnosis and Therapy.

Authors:  Sahar Esfandyari; Hoda Elkafas; Rishi Man Chugh; Hang-Soo Park; Antonia Navarro; Ayman Al-Hendy
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

Review 6.  Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review.

Authors:  Jing Wang; Wanru Liu; Dehai Yu; Zongxing Yang; Sijie Li; Xiguang Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-13

7.  Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure.

Authors:  Khadijeh Bahrehbar; Mojtaba Rezazadeh Valojerdi; Fereshteh Esfandiari; Rouhollah Fathi; Seyedeh-Nafiseh Hassani; Hossein Baharvand
Journal:  World J Stem Cells       Date:  2020-08-26       Impact factor: 5.326

Review 8.  Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.

Authors:  Sahar Esfandyari; Rishi Man Chugh; Hang-Soo Park; Elie Hobeika; Mara Ulin; Ayman Al-Hendy
Journal:  Cells       Date:  2020-10-08       Impact factor: 6.600

Review 9.  Mesenchymal stem cells: ideal seeds for treating diseases.

Authors:  Guanwen Gao; Chenyang Fan; Weiquan Li; Runzhang Liang; Chuzhong Wei; Xiaojie Chen; Yue Yang; Yueyuan Zhong; Yingqi Shao; Yi Kong; Zesong Li; Xiao Zhu
Journal:  Hum Cell       Date:  2021-07-16       Impact factor: 4.374

Review 10.  The Therapeutic Effect of Stem Cells on Chemotherapy-Induced Premature Ovarian Failure.

Authors:  Haoran Chen; Chi Liu; Shaomi Zhu; Shaowei Li; Qinxiu Zhang; Linjiang Song; Xin Liang
Journal:  Curr Mol Med       Date:  2021       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.